GSK, Ranbaxy settle over Valtrex

In another chapter in the Valtrex case, Ranbaxy and Glaxo have reached an agreement in which Ranbaxy will introduce its generic copies of Valtrex (valacyclovir) in the U.S. in the latter part of 2009 and will have 180 days of exclusivity to sell the product there.

The International Herald Tribune separately noted: Earlier this year, GlaxoSmithKline approved further development of a respiratory drug by Ranbaxy under a research and development collaboration pact between the two companies.

Under that pact, Ranbaxy could receive up to US$100 million in milestone payments from GSK if any of jointly developed drugs makes it to the market. It also retains the right to co-commercialize the products in India and earn royalties on overseas sales.